Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06208956
Other study ID # 2023-2105
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 20, 2024
Est. completion date February 29, 2024

Study information

Verified date January 2024
Source West China Hospital
Contact Li Zhou
Phone 18980606160
Email zlmz@wchscu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

104 patients who undergo painless colonoscopy from January 20,2024 to February 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 during the whole process.


Description:

104 patients who undergo painless colonoscopy from January 20,2024 to February 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1.For all patients, if Ramsay sedation scale score reach 3, colonoscope will be inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy. The primary outcome is the occurrence of hypotension. Key secondary outcomes are time-weighted average (TWA), area under the threshold (AUT) and cumulative duration of hypotension, as well as the maximum reduction in BP. Other secondary outcomes include(1) the incidence of bradycardia, hypoxemia or body movement;(2) discharge time (from the end of colonoscopy to discharge); (3) patients and endoscopists' satisfaction score (using an 11-point Likert scale, with 0 indicating "very dissatisfied" and 10 indicating "very satisfied"); (4) the incidence of dizziness, fatigue, or nausea and vomiting


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 104
Est. completion date February 29, 2024
Est. primary completion date February 29, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients aged above 18 years 2. American Society of Anesthesiologists (ASA) physical status of 1-2 3. Patients scheduled for sedation colonoscopy Exclusion Criteria: 1. Emergency patients 2. Body weight < 40 kg or >100 kg 3. Allergy to dexmedetomidine, propofol in this trail, a previous adverse reaction to dexmedetomidine or propofol 4. Pregnancy or lactation 5. Drug abusers 6. Participation in other clinical studies within the previous 3 months 7. renal impairment (glomerular filtration rate < 60 ml/min), significant hepatic impairment (ascites, cirrhosis, or with international normalized ratio(INR) >1.5)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexmedetomidine
In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 µg kg-1 for 10 min, then infusion at 0.3 µg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
Propofol
Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
West China Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome is the incidence of hypotension Hypotension is defined as 20% decrease from baseline systolic blood pressure (SBP) or diastolic blood pressure (DBP), or SBP < 90, and/or DBP < 50 mmHg The time during colonoscopy, an average of 15 minutes
Secondary Area under the threshold (AUT) of hypotension AUT=depth of hypotension below (a 20% decrease in baseline SBP or DBP) or (90 mm Hg of SBP or 50 mm Hg of DBP)× time in minutes spent of hypotension. As an example, a patient undergoes colonoscopy that lasts 15 min, in which he experiences 2 episodes of hypotension, all lasting for 1 min and all with a minimal SBP of 80 mm Hg. The AUT = 2 min × (90 -80= 10 mm Hg under the SBP threshold of 90 mm Hg) = 2×10 = 20 mm Hg per minute. The time during colonoscopy, an average of 15 minutes
Secondary Time-weighted average (TWA) TWA is calculated as the AUT divided by the total duration of colonoscopy The time during colonoscopy, an average of 15 minutes
Secondary Cumulative duration of hypotension The total time of patients experience hypotenion(hpotension defined as 20% decrease from baseline systolic blood pressure (SBP) or diastolic blood pressure (DBP), or SBP < 90, and/or DBP < 50 mmHg) The time during colonoscopy, an average of 15 minutes
Secondary Maximum reduction in blood pressure (BP) Maximum reduction in systolic blood pressure (SBP) ,diastolic blood pressure (DBP) and mean arterial pressure (MAP) from baseline The time during colonoscopy, an average of 15 minutes
Secondary The incidence of bradycardia Bradycardia is defined as heat rate(HR) <50 beats/min The time during colonoscopy, an average of 15 minutes
Secondary The incidence of hypoxemia Hypoxemia is defined as oxygen saturation (SpO2)<90% The time during colonoscopy, an average of 15 minutes
Secondary The body movement The twisting of the patient's body due to the stimulation of the colonoscopy, making it difficult to proceed with the procedure The time during colonoscopy, an average of 15 minutes
Secondary Discharge time From the end of colonoscopy to discharge From the end of colonoscopy to discharge,an average of 40 minutes
Secondary Patients satisfaction score Using an 11-point Likert scale, with 0 indicating "very dissatisfied" and 10 indicating "very satisfied" When the patient is fully awake after colonoscopy,an average of 5 minutes
Secondary Endoscopists'satisfaction score Using an 11-point Likert scale, with 0 indicating "very dissatisfied" and 10 indicating "very satisfied" At the end of colonoscopy,an average of 15 minutes
Secondary The incidence of dizziness The investigators consider it dizziness if patients fell any dizziness From the end of colonoscopy to discharge,an average of 40 minutes
Secondary The incidence of fatigue The investigators consider it fatigue if patients fell any fatigue From the end of colonoscopy to discharge,an average of 40 minutes
Secondary The incidence of nausea and vomiting The investigators consider it nausea and vomiting if patients fell any nausea and vomiting From the end of colonoscopy to discharge,an average of 40 minutes
See also
  Status Clinical Trial Phase
Completed NCT04101097 - Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
Completed NCT03247595 - Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy N/A
Completed NCT04214301 - An Open-Label Preference Evaluation of BLI800 Phase 4
Withdrawn NCT05754255 - Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center N/A
Recruiting NCT02484105 - Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction Phase 4
Active, not recruiting NCT02264249 - Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation N/A
Completed NCT01964417 - The Comparative Study Between Bowel Preparation Method Phase 3
Terminated NCT01978509 - The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies N/A
Recruiting NCT01685970 - Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy Phase 3
Completed NCT01518790 - Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children N/A
Recruiting NCT00748293 - Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet N/A
Completed NCT00779649 - MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial Phase 4
Completed NCT00671177 - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique N/A
Completed NCT00380497 - Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children Phase 4
Recruiting NCT00160823 - Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients Phase 3
Completed NCT00390598 - PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy Phase 2/Phase 3
Completed NCT00314418 - Patient Position and Impact on Colonoscopy Time N/A
Completed NCT00427089 - Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening Phase 3
Completed NCT00209573 - A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy Phase 3
Completed NCT05823350 - The Effect of Abdominal Massage on Pain and Distention After Colonoscopy N/A